Navitoclax-piperazine
CAT:
804-HY-44432-03
Size:
10 mM / 1 mL
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Navitoclax-piperazine
- CAS Number: 2143096-93-7
- UNSPSC Description: Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604) with anti-tumor activity[1].
- Target Antigen: Bcl-2 Family; Ligands for Target Protein for PROTAC
- Type: Reference compound
- Related Pathways: Apoptosis;PROTAC
- Applications: Cancer-programmed cell death
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/navitoclax-piperazine.html
- Purity: 99.73
- Solubility: DMSO : 125 mg/mL (ultrasonic)
- Smiles: O=C(NS(=O)(C1=CC=C(N[C@@H](CSC2=CC=CC=C2)CCN3CCNCC3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4
- Molecular Weight: 973.63
- References & Citations: [1]Sajid Khan, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med 25, 1938–1947 (2019).
- Shipping Conditions: Room Temperature
- Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
- Clinical Information: No Development Reported